Form 4: Alnylam Pharmaceuticals Executive Tolga Tanguler Reports Stock Sales Following RSU Vesting
SEC Form 4
EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Tolga Tanguler, reports the sale of company stock to cover tax obligations after restricted stock units vested.
Summary
- Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, filed a Form 4 on March 3, 2025, reporting transactions that occurred on February 27 and 28, 2025.
- On February 27, 2025, 1,667 restricted stock units (RSUs) vested, converting into common stock.
- Simultaneously, 1,667 shares were sold to cover minimum statutory tax withholding obligations.
- On February 28, 2025, a series of sales of common stock occurred, totaling 491 shares, at prices ranging from $236.51 to $244.32.
- Following these transactions, Tanguler directly owns 14,345 shares of Alnylam Pharmaceuticals common stock and 1,666 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral event. It reflects routine transactions related to executive compensation and tax obligations.
Industry Context
Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The stock sales may have a minor, temporary impact on the stock price due to increased selling pressure.
- The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2023 | Reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. |
| 02/27/2025 | 1,667 restricted stock units vested and were released. |
| 02/27/2025 | Shares sold to cover tax obligations. |
| 02/28/2025 | Series of sales of common stock occurred. |
| 03/03/2025 | Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.